START FREE TRIAL
Home Healthcare Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

$19.00

SKU: VRTX-1 Category:

Description

Vertex Pharmaceuticals’ Hidden Kidney Disease Opportunity: A Pivotal FDA Decision Looms!

 

Vertex Pharmaceuticals Inc. reported its third-quarter 2026 financial results with total revenue increasing 12% year over year, supported by growth across both U.S. and international markets. The company’s revenue diversification improved, driven by its cystic fibrosis (CF) franchise alongside contributions from recently launched therapies CASGEVY, JOURNAVX, and Palsonify following the acquisition of Crinetics Pharmaceuticals. CF revenue grew 8% year over year, with ALYFTREK sales leading growth; the medicine now treats over 18,000 patients globally and is approved or under review for younger patient populations and additional mutations. CASGEVY in severe sickle cell disease and transfusion-dependent beta thalassemia showed 30% sequential revenue growth, with infusion rates and patient initiations increasing steadily. The pain franchise led by JOURNAVX displayed strong prescription growth and expanded payer coverage, although net revenue continues to be affected by a significant gross-to-net discount necessitated by ongoing patient support programs.